Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05974631
Other study ID # SDR 22-185
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 3, 2024
Est. completion date July 30, 2027

Study information

Verified date April 2024
Source VA Office of Research and Development
Contact Melanie S Harned, PhD
Phone (206) 277-3650
Email melanie.harned@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Posttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Although evidence-based treatments for PTSD reduce suicide risk, Veterans at high risk for suicidal behavior rarely receive these potentially life-saving treatments. Prior research suggests that a treatment that combines Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure protocol (DBT PE) for PTSD improves both PTSD and suicide-related outcomes. This study will evaluate whether DBT + DBT PE improves these outcomes more than Prolonged Exposure plus suicide risk management, the gold standard VA care for this population. The proposed study will also examine factors that make it easier and harder to implement these treatments in VA settings. The results will help to inform treatment guidelines for this high-priority Veteran population.


Description:

Background: Posttraumatic stress disorder (PTSD) is a significant risk factor for suicide among Veterans. Evidence-based psychotherapies (EBPs) for PTSD reduce suicide risk, but Veterans at elevated acute risk for suicide, such as those who have engaged in self-directed violence (SDV), rarely receive these treatments. This is largely due to the historical exclusion of high-risk individuals from PTSD treatment trials, which has resulted in a lack of evidence-based guidance about indicated treatments for this population. Without such guidance, clinicians are often reluctant to use EBPs for PTSD with suicidal individuals. A treatment that combines Dialectical Behavior Therapy (DBT), a suicide-focused EBP, with the DBT Prolonged Exposure (DBT PE) protocol for PTSD has been developed for this high-risk population and shows promise in reducing both SDV and PTSD while being feasible, acceptable, and safe to deliver. However, a large-scale randomized controlled trial (RCT) is needed. This study will compare the effectiveness of DBT + DBT PE to the current VHA gold standard of care for this population, Prolonged Exposure therapy augmented with suicide risk management (PE + SRM), while also examining the potential for implementation of both interventions in VHA. Significance: There is a critical gap in knowledge about how to treat PTSD among individuals at high risk for suicidal behavior. As a result, VA/DoD Clinical Practice Guidelines do not specify indicated treatment strategies for this population. Experts have recommended two approaches to facilitate the safe and effective use of EBPs for PTSD with individuals at elevated acute suicide risk, including combining these treatments with suicide-focused EBPs or augmenting them with suicide risk management strategies. This project will help to fill this critical gap by rigorously evaluating these two approaches among Veterans with SDV. The results will provide important information to inform guidelines about indicated treatments for this high-risk population. Innovativeness: This will be the first large-scale RCT to evaluate treatments for PTSD among Veterans who have engaged in SDV, an HSR&D high priority group. The DBT + DBT PE intervention is the first treatment designed to address both SDV and PTSD, and results will indicate if this novel treatment improves outcomes compared to the current VHA gold standard of care. To facilitate more rapid implementation of these findings into clinical practice, implementation barriers and facilitators for both treatments will also be evaluated. Specific Aims: This study will randomize 200 Veterans with PTSD, recent and repeated SDV, current suicidal ideation, and emotion dysregulation to DBT + DBT PE (intervention) or PE + SRM (control). Aim 1 will test the hypothesis that DBT + DBT PE will be superior to PE + SRM in improving clinical outcomes and engagement in trauma-focused treatment. Exploratory analyses will examine Veteran characteristics that may predict better engagement and outcomes in DBT + DBT PE versus PE + SRM. Aim 2 will examine barriers and facilitators to implementation of both treatments. Methods: This is a multi-site hybrid type 1 effectiveness-implementation trial. Veterans will be treated in outpatient settings at three VA sites and assessed at 5 points over 18 months. A mixed-methods approach will be used to evaluate barriers and facilitators to implementation, including conducting interviews with 45 key stakeholders (Veterans, providers, and leadership). Primary Outcomes/Endpoints: Primary outcomes will be reductions in SDV episodes at 18-month follow-up and reductions in PTSD severity at post-treatment. Implementation/Next Steps: This project will provide much-needed information about how to safely and effectively treat PTSD among Veterans at elevated acute risk for suicide. If one or both treatments are found effective, Aim 2 will provide vital information about how to maximize future implementation success. Future implementation activities would be coordinated with the investigators' national operational partners.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date July 30, 2027
Est. primary completion date April 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PTSD - Recent and repeated self-directed violence - Current suicidal ideation - Emotion dysregulation - Veteran eligible for VHA mental health care at participating site (Seattle, Minneapolis, and Durham VAs) - Age 18+ - Willing to participate in all study activities Exclusion Criteria: - Unable to maintain safety independently - Currently engaged in and/or recent (past year) history of receiving a sufficient dose of DBT or PE - Plan to move away or be unavailable for >4 weeks in the next 18 months - Unable to sufficiently comprehend study procedures due to lack of English proficiency or moderate to severe cognitive impairment

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dialectical Behavior Therapy
Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
Dialectical Behavior Therapy Prolonged Exposure protocol
DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
Prolonged Exposure therapy
Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
Suicide risk management
Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.

Locations

Country Name City State
United States Durham VA Medical Center, Durham, NC Durham North Carolina
United States Minneapolis VA Health Care System, Minneapolis, MN Minneapolis Minnesota
United States VA Puget Sound Health Care System Seattle Division, Seattle, WA Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Treatment History Interview (THI) Non-VA psychotherapy, psychiatric crisis services, and psychotropic medications Baseline to 18 months
Other VA Service Use Form VA mental health service use and psychotropic medications Baseline to 18 months
Other Credibility Expectancy Questionnaire (CEQ) Total score (range = 1 - 7, higher is better) Baseline to 18 months
Other Client Satisfaction Questionnaire (CSQ) Total score (range = 8 - 32, higher is better) Post-treatment (4 months in PE + SRM, 12 months in DBT + DBT PE)
Other Dissociative Experiences Scale - Taxon (DES-T) Total score (range = 0 - 80, higher is worse) Baseline to 18 months
Other Trauma-Related Shame Inventory (TRSI) Total score (range = 0 - 72, higher is worse) Baseline to 18 months
Other Self-Compassion Scale (SCS) Total score (range = 1 - 5, higher is better) Baseline to 18 months
Other Borderline Symptom List - Behavioral Supplement (BSL-BS) Total score (range = 0 - 44, higher is worse) Baseline to 18 months
Other PTSD Checklist for DSM-5 (PCL-5) Total severity score (range = 0 - 80, higher is worse) Baseline to 18 months
Other Post-Traumatic Cognitions Inventory-9 (PTCI-9) Total score (range = 9 to 63, higher is worse) Baseline to 18 months
Primary Self-Injurious Thoughts and Behaviors Interview - Revised Short Form (SITBI-R-SF) Number of self-directed violence episodes Baseline to 18 months
Primary Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R) Total Severity Score (range = 0 - 200, higher is worse) Baseline to 18 months
Secondary Columbia - Suicide Severity Rating Scale (C-SSRS), Suicide Ideation subscales Total Score (range = 0 - 5, higher is worse) Baseline to 18 months
Secondary Brief Symptom Inventory (BSI) Global Severity Index (range = 0 to 4, higher is worse) Baseline to 18 months
Secondary Difficulties in Emotion Regulation Scale-16 (DERS-16) Total Score (range = 16 - 80, higher is worse) Baseline to 18 months
Secondary World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) General Disability Score (range = 12 - 60, higher is worse) Baseline to 18 months
Secondary Self-Injurious Thoughts and Behaviors Interview Revised Short Form (SITBI-R-SF) Non-suicidal self-injury frequency and remission; Suicide attempt frequency and remission Baseline to 18 months
Secondary Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R) PTSD diagnostic status Baseline to 18 months
See also
  Status Clinical Trial Phase
Terminated NCT05189977 - A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline Phase 1
Completed NCT01806168 - rTMS in the Treatment of PTSD N/A
Not yet recruiting NCT06194851 - Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD Phase 2
Completed NCT02187224 - Progesterone Effect on Individuals Diagnoses With AD and PTSD. Phase 2/Phase 3
Completed NCT02549508 - Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD N/A
Not yet recruiting NCT01940549 - Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder N/A
Completed NCT02012738 - Treatment of Trauma and Violence in the Townships of South Africa N/A
Not yet recruiting NCT06419959 - NightWare and Cardiovascular Health in Veterans With PTSD N/A
Terminated NCT03209882 - Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD) N/A
Completed NCT04891614 - The PRISM Pilot Trial for Post-Traumatic Stress Disorder N/A
Recruiting NCT05407337 - The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme N/A
Completed NCT02030522 - Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma N/A
Completed NCT01729325 - Prevention of Post-Traumatic Stress Disorder in Soldiers Phase 2
Completed NCT02053532 - Functional Brain Imaging in PTSD N/A
Not yet recruiting NCT02598024 - Treating Earthquake in Nepal Trauma (TENT) Trial 2016 N/A
Terminated NCT02237703 - Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD) N/A
Withdrawn NCT02356861 - LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans N/A
Not yet recruiting NCT06288594 - TraumaRelief App: A Pilot RCT Assessing Feasibility and Acceptability N/A
Completed NCT01847469 - Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence Phase 2
Completed NCT01691092 - PET Imaging of mGLuR5 With Drug Challenge N/A